MIM
TERN

Monashee Investment Management’s Terns Pharmaceuticals TERN Stock Holding History

Monashee Investment Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.8M Buy
300,000
+102,687
+52% +$4.22M 8.6% 1
2025
Q4 		$7.97M Buy
+197,313
New +$4.56M 4.49% 6
2024
Q4 		– Sell
-54,400
Closed -$454K – 97
2024
Q3 		$454K Buy
+54,400
New +$448K 0.05% 106
2024
Q2 		– Sell
-300,000
Closed -$1.97M – 135
2024
Q1 		$1.97M Buy
+300,000
New +$1.96M 0.23% 69
2023
Q1 		– Sell
-122,500
Closed -$1.25M – 69
2022
Q4 		$1.25M Buy
+122,500
New +$815K 0.54% 38

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Monashee Investment Management's TERN Position: Q1 2026 in Review

Monashee Investment Management increased its Terns Pharmaceuticals (TERN) stake by 52% in Q1 2026, buying an estimated $4.22M and bringing the position to 300,000 shares worth $15.8M. The position accounts for 8.6% of the portfolio, ranked #1.

Monashee Investment Management first reported a position in TERN in Q4 2022 and has held it in 5 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Monashee Investment Management held 300,000 shares of Terns Pharmaceuticals worth $15.8M as of Q1 2026.
  • Monashee Investment Management bought 102,687 Terns Pharmaceuticals shares in Q1 2026, an estimated $4.22M.
  • Terns Pharmaceuticals made up 8.6% of Monashee Investment Management's portfolio in Q1 2026, its #1 holding.
  • Monashee Investment Management first reported a position in Terns Pharmaceuticals in Q4 2022 and has held it in 5 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Monashee Investment Management's 13F filing for Q1 2026, filed 13 May 2026.